Why Merck & Co., Inc.’s (MRK) Stock Is Up 5.07%
As of Monday, May 12, Merck & Co., Inc.’s MRK share price has surged by 5.07%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Commentary & Analysis
What You Need to Know About Merck & Co., Inc.'s Q2 Earnings
Merck & Co., Inc.'s fiscal Q2 earnings report was released on Thursday, April 24. Let's dive in to see if (MRK) missed or beat analyst's expectations.Omar Beirat
Which Is a Better Investment, Jazz Pharmaceuticals plc or Merck & Co., Inc. Stock?
Learn more about whether Jazz Pharmaceuticals plc or Merck & Co., Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Aneeqa Nadeem
Which Is a Better Investment, Corcept Therapeutics Incorporated or Merck & Co., Inc. Stock?
Learn more about whether Corcept Therapeutics Incorporated or Merck & Co., Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Tudor Pop
Which Is a Better Investment, Intra-Cellular Therapies, Inc. or Merck & Co., Inc. Stock?
Learn more about whether Intra-Cellular Therapies, Inc. or Merck & Co., Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.Aneeqa Nadeem
Financial Summary
| Share Statistics | MRK | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $321,571.1 | $579.1 | 99% |
|
| Shares Out (Mil) | 2,472.0 | 43.0 | 98% |
|
| Institutional Ownership | 99.9% | 84.3% | 96% |
|
| Float (Mil) | 2,465.7 | 46.8 | 96% |
|
| Beta | 0.22 | 0.62 | 13% |
|
| Avg Daily Volume (000s) | 7,710 | 285 | 95% |
|
| Price Change (52-week) |
59.3% | 63.8% | 83% |
|
| Growth | MRK | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 9.4% | 6.7% | 56% |
|
| Net Income (5yr) | 20.9% | (1.4%) | 74% |
|
| EPS (5yr) | 21.2% | 14.9% | 70 |
|
| Dividends (5yr) | 5.8% | 0.0% | 95% |
|
| Cash Flow (5yr) | 22.7% | (14.9%) | 82% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 18 | 21 | 20 | |
| Current EPS | ($0.258) | $2.757 | $9.678 | |
| Month Ago EPS | ($0.236) | $2.731 | $9.584 | |
| # Rev Up | 0 | 8 | 1 | |
| # Rev Down | 1 | 5 | 0 | |
| Three Months Ago EPS | $2.082 | $5.141 | $9.764 | |
| Year/Year Chg | (85.0%) | (62.1%) | 46.1% | |
| Financials | MRK | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $65,768 | $272 | 98% |
|
| Net Income (TTM) (Mil) | $8,935 | ($11) | 98% |
|
| EPS (TTM) | $3.589 | ($0.500) | 81% |
|
| Operating Cash Flow (TTM) (Mil) | $17,890 | ($6) | 99% |
|
| Net Cash Flow (TTM) (Mil) | ($3,334) | $4 | 1% |
|
| Long-Term Debt (Q1) (Mil) | $46,673 | $7 | 98% |
|
| Enterprise Value (Q1) (Mil) | $340,489 | $522 | 99% |
|
| Valuation | MRK | Industry Median |
Percentile (All Stocks) |
|
| P/B | 7.01 | 2.73 | 85% |
|
| P/E | 36.4 | 20.5 | 75% |
|
| Dividend Yield | 2.6% | 0.0% | 81% |
|
| PEG (5yr hist) | 1.1 | 1.2 | 48% |
|
| Ratios | MRK | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 76.7% | 65.9% | 86% |
|
| Net Margin | 13.6% | 0.7% | 71% |
|
| ROA | 7.3% | (24.6%) | 81% |
|
| ROE | 19.0% | (19.7%) | 78% |
|
| Liabilities to Assets | 64.3% | 35.5% | 59% |
|
| F-Score | 4 | 3 | 34% |
|
Passing Stock Screens
As of 7/31/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Dogs of the Dow Screen
Factors: Yield, Value
Identifying contrarian plays among the Dow Jones industrial stocks.
| Performance Since Inception: | 4.3% |
| +/- S&P 500: | -3.2 |
FACTOR STRATEGY
Dogs of the Dow: Low Priced 5 Screen
Factors: Yield, Value
Identifying contrarian plays among the Dow Jones industrial stocks.
| Performance Since Inception: | 2.4% |
| +/- S&P 500: | -5.1 |
